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Abstract
Background: Treatment of major depression follows the guidelines from evidence-based
medicine established algorithms; however, 50% of patients diagnosed with major depressive
disorder do not respond to their first medication trial, and 70% may go through four treatment
attempts before achieving remission.
Purpose: To demonstrate the value of pharmacogenomic testing as a treatment-guidance
technology in patients with resistant depression and assess healthcare providers' motivation to
adopt the technology.
Methods: A retrospective chart review of (N = 73) patients' treatment response measured by the
pre-post PHQ-9 depression scale after pharmacogenomic guided medication intervention with
descriptive statistics and paired t-test. The project also assessed providers' motivation to adopt
and use pharmacogenomic testing by completing the providers' motivation scale (PMA) before
and after viewing an educational session on the subject.
Results: A significant improvement in mood with a mean decrease of 10 points in the post PHQ9 scores ( p = .000 < .001) in 53% of the subjects, and 33% had scores that ranked within
remission. Most patients (60%) responded to 1.3 medications post pharmacogenomic treatment.
The providers were motivated to learn new technology and gain knowledge derived from current
information for patient care.
Conclusions: These are significant findings corresponding to the new evidence research in
pharmacogenomics supporting the use of the technology as a therapeutic resource for treatmentresistant depression patients.
Keywords: pharmacogenomics, psychiatry, major depression, nursing, innovation
adoption
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A Quality Improvement Project to Assess the Value of
Pharmacogenomic Testing in Adults Diagnosed With Major Depression
Introduction
There is a treatment gap in adult patients diagnosed with a major depressive disorder who
have failed two or more medications and remain symptomatic or are considered to have
treatment-resistant depression (TRD). The practice guidelines for psychiatric evaluation and
treatment from the American Psychiatric Association (APA) (2015) recognize that individuals
may experience an inadequate response to medications or health and mood complications due to
psychotropics' adverse events. Authors like Giakoumatos and Osser (2017) and Stahl (2017)
agreed that there are no treatment guidelines for patients' genotypes who failed antidepressants
due to a lack of response or adverse events.
This quality improvement project compared Patient Health Questionnaire - 9 (PHQ-9)
scale score changes before and after medication’s guided intervention from pharmacogenomic
testing (PGx) in adult patients who failed more than two antidepressants. The goal was to
identify the value of pharmacogenomic testing as a personalized treatment resource in patients
with genomically idiosyncratic needs vs. the non-response to treatment as usual (TAU). A
second goal included the assessment of healthcare providers’ motivation to adopt this
technology.
Background
Major depressive disorder (MDD) has the highest prevalence in mental health conditions,
with a 7.1 % among the adult population in the United States (USA) (National Institute of
Mental Health, [NIMH], 2019). The results from the Sequenced Treatment Alternatives to
Relieve Depression (STAR-D) study in 2006 showed that 50% of these individuals did not
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respond to their first medication trial, and 70% of patients may go through four treatment
attempts before achieving remission (NIMH, 2006). Similar findings from Warden et al. (2007)
identified that less than 50% of MDD patients would achieve remission after two antidepressant
trials.
The STAR*D psychopharmacology algorithm presented four levels of antidepressant
management with subsequent treatment recommendations after each level's failure (Gaynes et al.
2008) (Appendix A). The first level starts with the use of citalopram. If the patient failed to
respond or could not tolerate it, will switch to level two with venlafaxine extended-release or
sertraline, or augmentation with bupropion sustained-release and cognitive therapy. For nonrespondent individuals, level three proposed trials of mirtazapine or nortriptyline and
augmentation with lithium or T3 thyroid hormone. Finally, level four recommends combining
mirtazapine and venlafaxine extended-release or monoamine oxidase inhibitors (MAOIs) like
tranylcypromine (Parnate).
Correspondingly, the psychopharmacology algorithm project at the Harvard South Shore
Program (Appendix B) by Giakoumatos and Osser (2017) incorporates the first-line use of
sertraline, escitalopram, or bupropion for the treatment of outpatient unipolar depression. If the
patient does not respond, switch to a dual-action agent like venlafaxine or mirtazapine. The
algorithm includes serotonin selective reuptake inhibitors (SSRIs) alone or combined with
lithium or Wellbutrin for augmentation, also transcranial magnetic stimulation (TMS),
supplements like omega-3s, and atypical antipsychotics. Patients who fail two antidepressants
will be considered to have treatment-resistant depression (TRD). The group guidelines suggest
reviewing the patient’s history, symptoms, past responses, comorbidities, family history, and

7
preferences before a third medication trial (APA, 2015; Giakoumatos & Osser, 2017; Stahl,
2017).
Polypharmacy is a practice that has increased in psychiatry over the last 20 years
(Shrivastava, 2019). Treatment-resistant depression (TRD) patients are frequently under
psychiatric polypharmacy with two or more prescriptions unless discontinuing a medication due
to adverse effects. The use of more than one medication increases drug interactions, potential
adverse effects, morbidity, and mortality (Sarkar, 2017). Johnston et al. (2019) and Mrazek et al.
(2014) found in a systematic literature review that TRD patients who have failed more than two
medication courses will experience a reduced health-related quality of life (HRQoL). According
to the authors, these patients will also have higher relapse rates, increased mortality, and
additional medical direct and indirect costs to society of $29 to 48 billion dollars a year.
The science of pharmacogenomics has been evolving since the 1960s, intending to find
genetically congruent medications based on the individual’s genetic markers or metabolic profile
(Charlab & Zhang, 2013). Different medical specialties, including psychiatry, benefit from
pharmacogenomics to identify patients’ metabolic biomarkers with strengths or weaknesses in
the Cytochrome P-450 (CPY450) family (pharmacokinetics), and variations in genetic
morphology receptors (genotype) that may affect drug response and result in SSRI resistance
(Vadodaria et al., 2019).
Currently, the Food and Drugs Administration (FDA) recognized four genes evidencebased verified pertinent to psychopharmacology, cytochrome P450 2D6 (CYP2D6), cytochrome
P450 2C19 (CYP2C19), human leukocyte antigen, B type, allele 15:02 (HLA-B*15:02), and
human leukocyte antigen, A-type, allele 31:01 (HLA-A*31:01), (Hicks et al., 2016; Miller,
2019). There is plenty of controversy around the use of pharmacogenomic testing frequently
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elicited by companies that advertise the test will predict medications for an individual. Recent
and ongoing clinical trials show that pharmacogenomic testing (PGx) offers patients congruent
medication alternatives compatible with their genotype needs.
Review of the Literature
This review of the literature explored pharmacogenomic testing as an alternative to guide
the treatment of patients who have failed two or more antidepressants. Search engines from 2014
to 2020 included the Cumulative Index of Nursing and Allied Health Literature (CINAHL),
PubMed Central of the National Library of Medicine, and Google Scholar for the medical
subject headings (MeSH): pharmacogenomics, psychiatry or psychiatric or mental health,
nursing, clinical guidelines, randomized controlled trials, and systematic reviews.
Inclusion criteria followed the levels of evidence I to II recommended by the National
Guideline Clearinghouse (U.S. Department of Health and Human Services, n.d.), focusing on
randomized controlled trials (RCT), clinical guidelines, controlled studies, prospective and
retrospective studies, and systematic reviews. The exclusion criteria was comprised of level IV
editorials, letters, opinion articles, six duplicated articles, and two ongoing pharmacogenomic
clinical trials in Europe and Oregon, United States.
Most articles were available through the University of Massachusetts EBSCO host
database. The search revealed 47 articles in the time frame for pharmacogenomics and
psychiatry or psychiatric or mental health and randomized controlled trials. The final selection
included 15 articles: the guidelines from the Clinical Pharmacogenetics Implementation
Consortium (CPIC) and the Dutch Pharmacogenetics Working Group, five Level I RCTs
comparing treatment as usual vs. pharmacogenomic testing, one review of three randomized
controlled trials, one open-label prospective study, one case-control study, and three systematic
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reviews. There were no results under pharmacogenomics and psychiatric nursing, and
randomized clinical trials. However, for the terms “nursing and clinical trials,” six nursing
articles included two Level IIB quasi-experimental retrospective studies, both covered in this
review.
Clinical Guidelines
The U.S. Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch
Pharmacogenetics Working Group in the Netherlands share therapeutic recommendations for the
dosing of antidepressants, including tricyclics (TCAs) and Selective Serotonin Reuptake
Inhibitors (SSRIs) (Bank et al., 2018; Fabbri, & Serretti, 2019). All clinicians who prescribe will
benefit from the guidelines recommendations appropriate for patients with genotype variances
(Hicks et al., 2015, 2016).
The guidelines identified two essential pharmacokinetic genes involving the metabolism of
most antidepressants (TCAs and SSRIs) based on levels of evidence I and II, cytochrome P450
2D6 (CYP2D6) and cytochrome P450 2C19 (CYP2C19) (Bank et al., 2018; Hicks et al., 2015,
2016). The classifications of genotypes are normal, intermediate, ultra-rapid, and poor
metabolizer. Both consortiums agree on the need for dose adjustment when prescribing
antidepressants to patients identified as ultra-rapid and poor metabolizers or consider an
alternative medication (Bank et al., 2018; Hicks et al., 2015, 2016). Lack of knowledge of the
patient's possible genotype variants will result in the prescriber's treatment as usual (TAU)
choices, perpetuating the potential failure, adverse events, or inappropriate polypharmacy.

Evidence-Based Psychopharmacology
Greden et al. (2019), in a rater patient-blind randomized controlled trial (RCT) of
treatment as usual (TAU) medications vs. the pharmacogenomic guided intervention (GUIDED)
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with N = 1167 MDD patients, found the guided group had significant results for response and
remission rates p = 0.013 and p = 0.007 respectively. However, results were not significant for
symptom improvement, possibly since some TAU group patients were already taking genetically
congruent medications. In a post hoc analysis of the GUIDED data, Dunlop et al. (2019) found
significant improvement, response, and remission rates at eight weeks using the Hamilton
Depression scale 6 (HAM-D6) in patients in the GUIDED group and the TAU group with the
prescription of personalized medications.
In a Level I RCT for outpatient and inpatient Spanish public hospitals, Pérez et al. (2017)
found that MDD patients in the pharmacogenomic guided group had a higher response and better
tolerability to antidepressants than TAU groups, but not sustained response. In China, Xiao-Xiao
et al. (2019) had comparable results in a Level II case-control trial. Individuals identified by
testing with the ABCB1 TT genotype of rs2032583 improved treatment response to selective
norepinephrine reuptake inhibitors (SNRIs).
Contrary to the previous results, Ruaño et al. (2020) randomized patients’ treatment at the
Institute of Living at Hartford Hospital based on their CYP2D6 genotype vs. TAU to compare
the length of stay (LOS) and readmissions rate (RAR) between groups. They found no statistical
differences between groups; however, the authors identified genetic polymorphisms in the study
population and recognized the barrier of physicians’ non-compliance with pharmacogenomic test
recommendations. Solomon et al. (2019) had similar inconsistent findings for treatment response
or improved clinical outcomes in PGx testing of CYP2D6 and CYP2C19.
A pragmatic randomized controlled trial by van der Schans et al. (2019) tested CYP2D6
in depressed elderly patients to determine the benefits of accelerating nortriptyline or venlafaxine
dose vs. non-pharmacogenomic testing (PGx) controlled group and a normal CYP2D6 group.
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The researchers found no significant mean time differences between groups to reach adequate
doses. However, more patients (n = 24) in the genotyped group who were poor and intermediate
metabolizers (PM, IM) reached medication levels vs. the control group (n = 16). The researchers
also found lower adverse events in the external control group (normal metabolizers) than the
genotype groups. The findings reflect the benefits of PGx for appropriate dosing in individuals
with PM or IM genotypes in accordance with the clinical guidelines.
In a review of three Level I RTCs, Altar et al. (2015) evaluated pharmacogenomic guided
medication versus treatment as usual (TAU) based on Hamilton – Depression 17 (HAM-D17)
and Beck Depression Inventory (BDI), respectively. Findings showed that patients with
pharmacogenomic guided treatment had a 2.3 higher odds ratio of clinical response than patients
in TAU. Congruent with these, Tanner et al. (2018) found in a Level II open-label prospective
study that patients with moderate to severe depression had a 31% greater improvement in
response and 15.2 % greater remission rates when using pharmacogenomic testing.
There are two Level II pharmacogenomic testing studies in recent nursing literature. One is
a quality improvement pre – post test design by Conley et al. (2020) using pharmacogenomic
testing in the psychotropic management of patients with chronic mental illness. The researchers
found that patients with psychotropics guided by PGx decreased symptoms, increased treatment
engagement, and improved community function. In a retrospective six-month pre-post chart
review of patients guided medications adjustments post pharmacogenomic testing, White et al.
(2018) identified patients improved tolerability and decreased side effects.
In systematic reviews of pharmacogenomic testing for patients’ outcomes, benefits, and
testing cost-effectiveness, Peterson et al. (2017) and Rosenblat et al. (2017) found mixed
evidence of cost-effectiveness and improved health outcomes in the literature. The researchers
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agreed that there were few pharmacogenomic randomized controlled trials before 2018, therefore
limited evidence. On the other hand, a retrospective cohort study from Sussman et al. (2019)
established the cost benefits of using pharmacogenomic testing with potential health care savings
of over $3,000.00 dollars a year in individuals with treatment resistant depression.
The validity and utility of pharmacogenomic testing in recent research illustrates the
improved response and remission rates for depression in patients with genotype deviations. It
also showed the opportunity to anticipate medication dosing, drug-gene interactions, response
deficits, or side effects (Benitez et al., 2015). The Food and Drug Administration (FDA)
recognizes pharmacogenomics’ use to identify individuals who will or will not respond to
medications, avoid adverse events, and improve drug response (FDA, 2020). Their guidelines
include drug labeling with data enforcing risks in drug exposure and adverse events, genotype
dosing recommendations, drug mechanisms, and drug target and disposition genes (FDA, 2019).
The agency also bounds pharmacogenomic testing companies from making false claims or
advertisements for predicting patient–medications response (FDA, 2019).

Theoretical Framework
The Diffusion of Innovation Theory by Everett Rogers (2003), provided the ground for
this DPN project (Appendix C). The communication model promotes the adoption of new
behaviors or ideas by the target groups, in this case, health professionals, organization leaders,
and patients. Rogers (2003) recognizes that the acquisition of ideas in a population takes time for
its adoption, and individuals will join at different times based on their needs and personal
characteristics.
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According to Rogers (2003) the five categories of innovation adopters are: innovators,
early adopters, early majority, late majority, and laggards. All will go through the stages of
awareness, the decision to adopt or reject, initial use, and continued use of the innovation at their
own pace. The individual’s choice to adopt the new idea will be based on five factors: 1) the
belief that the new idea is better than the old; 2) the idea must be consistent with the adopters'
values and needs; 3) level of difficulty to understand or use; 4) testing capability; 5) observable
results – outcomes (Rogers, 2003).
The diffusion process requires knowledge to engage, persuade, and maintain change
(Rogers, 2003). In a systematic review of oncology physicians' genomic literacy, Ha et al. (2018)
examined Rogers’ three types of knowledge in the translation and adoption process: awareness,
how-to, and knowledge principles. Their findings reflected that 87% of these physicians had an
awareness of the different cancer genetic assays, but only 20 to 40% were ordering the assays.
This data confirms that awareness is not tantamount to applying new technology.
The slow adoption of pharmacogenomic testing by healthcare providers is an ongoing
debate that resonates with the Diffusion of Innovation Theory. Some scientific groups are in
support, while others prefer to continue with the traditional treatment as usual or TAU until more
evidence is available. In a meta-data analysis of 36 studies, Veilleux et al. (2020) found that
physicians were not ordering pharmacogenomic testing due to recognizing their knowledge
deficits in the topic. This project included an education component to promote providers with an
evidence-based understanding of pharmacogenomics and the conviction that PGx testing
adoption leads to improved patient care.
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Methods
This quality improvement program did a record review in a community mental health
agency in Western Massachusetts of their current use of pharmacogenomic testing to identify
patients’ response and remission to genetically sound medications measured by the Patient
Health Questionnaire 9 (PHQ-9). The project also surveyed providers’ motivation to adopt
pharmacogenomics before and after an educational presentation to motivate and strengthen their
adoption and knowledge in using the technology.
The timeline (Appendix D) started in October 2020 with a two-year retrospective chart
review from November 2018 to October 2020 of patients diagnosed with major depression
(MDD) who received pharmacogenomic testing. Next, providers including physicians, nurses,
administrators, and a group of therapists received a Survey Monkey consent via email to
participate in the project (Appendix E), and if acceded, continued to the Provider Motivation
Adoption (PMA) Pre-scale (Appendix F). The scale measures motivation to adopt and maintain
the use of innovative technology (Hatz et al., 2017). During November 2020, the providers
received a 15 minutes video powerpoint education in pharmacogenomics and related literature
(Appendix G). A post-survey (Appendix H) was available to the providers and staff during
February 2021.
For the chart review, the inclusion criteria were adults over 18 years old diagnosed with
MDD, a history of two or more medication failures, and previous pharmacogenomic testing at
the agency. Exclusion criteria were patients with other diagnoses (e.g., bipolar disorder),
concurrent transcranial magnetic stimulation treatment (TMS), or drop out from treatment before
guided intervention.
This project did not require a budget investment by the agency since the data is already
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part of the electronic medical record (EMR), and providers could fill the PMA scales online.
The education program was a 15 minutes video PowerPoint delivered by email to watch in their
own time. Using the electronic platforms provided access and saved the cost of materials.

Goals, Objectives, and Expected Outcomes
The project’s main goal was to assess the value of pharmacogenomic testing in the
psychotropic management of adults diagnosed with major depressive disorder (MDD) who have
failed two or more medications. A secondary goal was to promote the adoption and use of
pharmacogenomic testing by medical providers. To achieve this, the student followed these
objectives (Table A1):
1. Evaluated the response to pharmacogenomic guided medications in patients tested from
2018 to 2020 with the Patient Health Questionnaire - 9 scales by February 2021.
2. Assessed providers' motivation to adopt pharmacogenomic testing with the provider
motivation adoption scale (PMA scale) (Hatz et al., 2017) during November 2020.
3. Promoted providers' adoption of pharmacogenomic testing with education on the
topic by November 2020.
The expected outcomes were greater efficacy in treating depression in the project subjects
as evidenced by improved treatment response with a minimum drop in five points from baseline
in the Patient Health Questionnaire - 9 scale, or remission with four or less total points on the
scale. The secondary outcome expected and increased in provider motivation to use
pharmacogenomic technology measured by an increase in the PMA scale results after the
education in the topic.
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Project Site and Population
A community mental health agency in Western Massachusetts was the site for this project.
The agency serves a diverse population of over 12,000 individuals and families from different
socio-economical, racial, and cultural backgrounds. The agency is composed of multidisciplinary
mental health professionals who offer a variety of behavioral and psychopharmacology
modalities. In 2018 the medical director incorporated pharmacogenomic testing for medication
guidance in patients non-responsive to treatment, and in 2019 added the Transcranial Magnetic
Stimulation (TMS) program.
The medical team comprises psychiatrists, child psychiatrists, primary care physicians,
advanced practice nurses, and registered nurses. Providers follow treatment as usual (TAU)
medication protocols based on major depression (MDD) guidelines. Pharmacogenetic testing is
available in the agency and covered by MassHealth, Medicaid, Medicare, and some commercial
insurances. However, due to providers’ time limitations with a high volume of patients and
possible knowledge gaps in using the pharmacogenomic report, the testing is not used as a
standard practice in treatment resistant patients who failed the recommended algorithms.
Description of the Group
The retrospective review's target population was 123 records of adults diagnosed with
MDD who failed at least two antidepressants and had pharmacogenomic testing from November
2018 to October 2020. The providers' educational intervention included four physicians, five
nurses, three administrators, and a group of 15 randomly selected psychotherapists. The group
received via email a Survey Monkey consent to participate in the project (Appendix E), and if
acceded, continued to the Provider Motivation Adoption (PMA) Pre-scale (Appendix F) and
video education program.
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Measurement Instruments
For the record review, patients had filled the self-assessment Patient Health Questionnaire
- 9 (PHQ-9) (Appendix I) ideally on their first interview and during treatment. The PHQ-9 is an
ordinal scale that assesses degrees of depression. Scores ranging between 5 - 9 are mild
symptoms, and scores ranging from 10 – 27 are considered depression from moderate to severe.
Levis et al. (2019) found a combined sensitivity of 0.88 and specificity of 0.85 for a cut-off score
of 10 or above.
The educational session and assessment of motivation, providers were engaged in the
project during the monthly zoom team conference and received by email a pre and post-test
based on the Physician Motivation Adoption (PMA) scale from Hatz et al. (2017) (Appendix F,
Appendix H). The PMA scale is a five-point Likert scale that measures physicians’ motivation to
adopt different medical technology or devices (Hatz et al., p. 533). It has excellent reliability and
validity with an acceptable Kaiser-Meyer-Olkin (KMO) test value of 0.76. For this project, and
after obtaining authorization from the author (Appendix J), the scale was renamed the Provider
Motivation Adoption scale to allow non-physician providers to participate in this project
(Advanced Practice Nurse, Nurses, clinicians, and administrators). The PMA scale was labeled
as Pre-PMA (Appendix F) for the initial assessment and Post-PMA (Appendix H) after the
educational intervention with additional comments option in both.

Providers Education Program
Due to Covid quarantine and providers’ availability limitations, the DNP student submitted
by email a video education program in pharmacogenomics (Appendix G) for the agency
providers, including psychiatrists, nurses, and therapists, after the online pre-test assessment. The
content included definitions of pharmacogenomics, clinical guidelines, FDA regulations, and
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strategies to understand the pharmacogenomic report's clinical application. The presentation
combined various sources, including authorized material from the Neuroscience Education
Institute in California, USA (Appendix K). After one to two months from the video education,
the providers received the post-PMA via SurveyMonkey email link.
Data Collection and Analysis
The data was collected from patients' pharmacogenomic reports at the Myriad AssureRx
secure website, the PHQ-9 scores, and their demographic data from the electronic health records.
Thirty subjects were missing PHQ-9 scales and called to update their information. The input was
organized in an excel sheet and transferred to the Statistical Package for Social Sciences (SPSS)
program (Appendix L ). The statistics included patients' demographics (age, gender, raceethnicity), changes in mood response or remission based on PHQ-9 scales pre-post
pharmacogenomic guided treatment, number of medications before and after the PGx guided
report, comorbid personality disorders (borderline personality disorder and history of substance
use), and genotype report data (e.g., CPY450 variations).
The analysis included descriptive statistics of the group demographics, an average of
medications before and after pharmacogenomic testing, comorbid borderline personality disorder
vs. history of substance use responses, and genotype findings. Paired t-test was used to examine
the difference between PHQ-9 scores before and after pharmacogenomic guided medication. Due
to sample size limitations and cross-over comorbid diagnoses within the sample subjects,
inferential statistics were not appropriate. Nonetheless, crosstabulation allowed to examine the
relation of post-PHQ-9 scores and subjects with comorbid borderline personality disorder and
substance use history.
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The providers' motivation data were obtained from their responses to the PMA pre-post
scales via SurveyMonkey on their website under the student's secure account. Descriptive
statistics described their responses and motivation to adopt the new technology after the
education intervention.

Ethical Considerations and Protection of Human Subjects

To comply with the University of Massachusetts, Amherst (UMass) Internal Review Board
(IRB), the student obtained the agency approval for the Quality Improvement Project for the
retrospective chart review (Appendix M). The agency providers received a consent form for their
participation in the PMA survey in early November 2020. The pharmacogenomic reports from
Myriad AssureRx are the product the agency uses. The student discloses no bias or conflict of
interest in the pharmacogenomic report or the company.
The Health Insurance Portability and Accountability Act ([HIPPA], 2003) requirements
for retrospective studies emphasize the use of patient non-identified data. Therefore, patients’
data were assigned a number in the pharmacogenetic reports, PHQ-9 scales, patients’ diagnoses,
and demographics. The student destroyed any list of cases after the data was collected. All
electronic files containing identifiable information are password protected to prevent
unauthorized users' access, and only the project coordinators have access to the passwords.
The nursing Code of Ethics standards reiterate the nurse's responsibility to guarantee the
patient's interests, safety and protect their rights (Winland-Brown et al., 2015). The student
guaranteed the patient's and staff's best interests, protected their confidentiality and safety during
this review by avoiding any identifiable information and protecting the project's data.
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Results
The record review was completed between October 2020 to February 2021. It included
123 records of adults over 18 years old diagnosed with major depressive disorder (MDD) who
failed more than two antidepressants and had pharmacogenomic testing (PGx) for treatment
guidance. The final sample consisted of 73 cases that met the inclusion criteria. Patients with a
diagnosis of bipolar disorder (16), in concurrent transcranial magnetic stimulation TMS (10), and
closed before followed PGx treatment (24) were excluded. The providers' survey, including
video education, was emailed to 27 physicians, nurses, clinicians, and administrators, out of
which 12 responded to the Pre-PMA survey, and only three responded to the Post-PMA survey
despite reminders by email.
Record Review Demographic Characteristics
The 73 patients diagnosed with major depression ages ranged from 18 to 71, with a mean
age of 44 years old. A majority (72.6% ) were females and 27.4% males, predominantly White
European-American 86.3%, with White Hispanic 8.2%, and 5.5% Black African-American.
Before pharmacogenomic testing, 17 patients (23.3%) had an average of four medications,
16 (21.9%) had eight to eleven medications, and 15 (20.5%) had five to seven medications. The
average number of medications after pharmacogenomic guided medication was 1.36 in 44
patients (60.3%), and 18 (24.7%) had two to four medications before responding to treatment.

Pre-Post PHQ-9 Scores Findings

To examine the benefits of pharmacogenomics testing, Table 2 presents the pre-post PHQ9 depression scores after the pharmacogenomic guided medication intervention. The PHQ-9
depression scale measures depression severity where scores indicate: 0-4 minimal depression, 5-
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9 mild depression, 10-14 moderate depression, 15-19 moderate to severe depression, 20-27
severe depression.
Table 2
PHQ-9 Pre – Post and Difference Scores
Pre
PHQ-9 score
N
Mean
Std.Deviation
Median
Mode

Post
PHQ-9 score

Difference
PHQ-9 scores

64

65

63

18.95

9.08

10

4.18

6.25

5.60

19.50

7

12

22

5

13

The post-PHQ-9 produced a mean of 9.08 points with 6.25 standard deviations (SD) vs. a
pre-PHQ-9 mean of 18.95 with 4.18 SD. This represents a mean difference or decrease of 10
points in the post-measurement or treatment response with more than five points decrease.
Interestingly, the post scale (n = 65) has a mode or most frequent score of five points (minimal
depression) in 13.7% of the group vs. a previous mode of 22 (severe depression) in 12.3% of the
subjects in the pre-PHQ-9. It must be noted there were nine missing values in the pre-data and
eight missing in the post-scores. The discrepancy resulted from the PHQ-9 scale not being part of
the agency's routine measurements for all patients; therefore, not all subjects had the scale before
or after the PGx testing. For this reason, the analysis follows the reported data from SPSS.
Nonetheless, the missing values, the sample of 64 subjects in the pre-PHQ-9, has a normal
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distribution with a Pearson's coefficient of skewness Sk2 = -.39 (-0.5 to 0.5 approximately
symmetric).

To further assess the difference between the pre-post PHQ-9 scales, a paired t-test was
used with results presented in Table 3.

Table 3
Paired Samples Test

Pair 1

Pre-PHQ-9 Score

Mean Std.
Std.
Deviation Error
Mean
10
5.605
.706

95%
Confidence
Interval of
the
Difference
Lower

Upper

8.588

11.412 14.412

t

Df

62

Sig.
(2tailed)
.000

Post-PHQ-9 Score
Note. Correlation r =.488

The paired t-test for the pre-post PHQ-9 scores revealed a moderate association with a
correlation of r=.488, indicating a positive change between the scales where scores decreased
linearly after the pharmacogenomic intervention. The data reflects a statistical mean difference
with significant p=.000 < .001, which reveals patients’ response to treatment with a significant
decrease of 10 points mean in the post PHQ-9 scores or treatment response (5 – 9 mild
depression) after the pharmacogenomic guided medication changes. The results do not suggest
remission due to most of the scores in the "5-9 mild depression and 10-14 moderate depression "
values in the post scale.
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This project did not include patients with multiple comorbid diagnoses (e.g., anxiety,
post-traumatic stress), except subgroups with a diagnosis of borderline personality disorder
(BPD) and substance use, as illustrated below in Table 4.
Table 4
Gender Comorbid Borderline Personality and History of Substance use
Gender
Male

Female

N

%

N

%

No Comorbid Diagnosis
or Substance Use

3

4%

22

30%

Substance Use Hxa

14

19%

25

34%

Borderline
Personality Disordera

4

5%

15

20%

Borderline Personality
& Substance Use Hxa

4

5%

8

10%

Note. N = 73
a

Some of the percentages exceed 100% due to overlap.
A subgroup with the diagnosis of comorbid borderline personality disorder (BPD) was

identified in 26% of individuals. Twenty percent were females with predominant ages of 29 to 39
and 51 to 50 (n=6 in each age subgroup). In terms of comorbid borderline personality disorder
and substance use history, the results identified eight (10%) of females with comorbid
personality diagnosis and substance use history. There were four (5%) males diagnosed with
BPD and four (5%) with combined BPD and substance use history. The more significant number
of females in the sample and the fact that they have diagnosed BPD 3:1 ratio to males are
portrayed in the results.
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There was a past substance use history in 39 (53%) of the 73 patients, which included
alcohol and cannabis and/or cocaine and/or opiates (19.2%,) cannabis (8.2%,), opiates (6.8%),
cocaine (1.4%), opiates and cannabis (1.3%), and active cannabis use (11.8%). In the gender
subgroups, 19% of the males, half of the subgroup, had past substance use vs. 34% of the
females. The “National Survey on Drug Use and Health” by McCance-Katz (2019) identified
19.3 million Americans over 18 years old with a substance use disorder (SUD), 20.6 million with
a mental illness, and an overlap of 9.5 million individuals with both SUD and mental illness. The
sample data had a higher proportion; more than half of the patients had a SUD history, probably
due to the sample size limitation.
To explore any relation in the post PHQ-9 scales of patients with comorbid BPD or
substance use history vs. no comorbidities, Table 5 shows a crosstabulation.
Table 5

Post PHQ-9 in Patients With no Comorbidities vs. BPD and Hx. SUD

Post PHQ-9 scores

No Comorbid
Diagnosisa

Borderline
Personality
Disordera
N
%

History of
Substance Usea

N

%

0–4

14

21%

1

1.5%

7

10%

5-9

15

23%

9

13%

12

18%

10 – 14

10

15%

2

3%

6

9%

15 - 19

4

6%

3

4%

2

3%

20 - 27

2

3%

4

6%

6

9%

Note. N=65. Missing values.
a
Subjects and percentages may overlap

N

%
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All three subgroups had most subjects post PHQ-9 scores in the “5 – 9 mild depression”
range with a highest 23% in the “no comorbid diagnosis,” 18% “history of substance use,” and
the lowest 12% in “borderline personality disorder.” We can observe 21% and 10% of “0 – 4
none to minimal depression” or remission in the “no comorbid diagnosis” and “history of
substance use” subgroups. The patients in the history of substance use had more scores 10% >
1.5% in the “0 – 4 none to minimal depression” and 18% > 12% in the “5 – 9 mild depression”
than the BPD subgroup. The findings indicate that individuals in the borderline personality
disorder subgroup had lower responses post pharmacogenomic intervention.

Other interesting findings included the subjects' genotypes for the serotonin transport gene
SLC6A4 with a 45.2% L/S variant "Intermediate Sensitivity" and a 27.4% S/S variant with
"Increased Sensitivity." These variants will result in decreased serotonin transport and reduced
response to SSRIs antidepressants. The serotonin receptor genes HTR2A A/A had a 15.1% and
the HTR2A G/G a 39.7% of the subjects. In both cases, evidence research demonstrated 15% and
42% of potential side effects to SSRIs, respectively. Table 6 below presents the sample findings
for the cytochrome P450 enzyme system's responsible for metabolizing most substances and
medications.
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Table 6
Sample Distribution Cytochrome P450 Enzymes
CYP
1A2

CYP
2B6

CYP
2C19

CYP
2C9

CYP
2D6

CYP
3A4

UGT
1A4

UGT
2B15

46.6%

56.2%

68.5%

63.0%

61.6%

83.6%

75.3%

78.1%

Intermediate
Metabolizer

2.7%

37.0%

20.5%

35.6%

19.2%

16.4%

2.7%

21.9%

Poor
Metabolizer

0.0%

5.5%

2.7%

1.4%

11.0%

0.0%

0.0%

0.0%

Ultrarapid
Metabolizer

50.7%

1.4%

8.2%

0.0%

8.2%

0.0%

21.9%

0.0%

Normal

Note. N = 73
The most common genotypes in the sample (50.7%) were with the ultrarapid (fast
metabolizer) enzyme CYP1A2. This finding is not relevant for our discussion since the enzyme
is not responsible for metabolizing antidepressants. However, it is the main pathway for
medications like Clozaril, Zyprexa, and others (Flockhart, 2008) to treat psychosis and
schizoaffective disorders.
The following frequent group was in the “intermediate metabolizer” (IM) category with
37% for the CYP2B6 enzyme responsible for the antidepressant bupropion (Wellbutrin), and the
CYP2C9 enzyme 35.6%, which participates in the metabolism of amitriptyline (Elavil), doxepin
(Sinequan), fluoxetine (Prozac), venlafaxine (Effexor), and valproic acid (Depakote) (Flockhart,
2008). The enzyme CYP2C19, which metabolizes citalopram and escitalopram (Celexa and
Lexapro) and several TCAs, had a 20.5% IM, and UGT2B15, which metabolizes sedatives often
used in depressive disorders, had 21.9% IM.
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Finally, 19.2% of the patients were "Intermediate Metabolizer" and another 11% "Poor
Metabolizer for the enzyme CYP2D6, which metabolizes 25% of all prescription drugs and
many antidepressants like Prozac, Paxil, Cymbalta, Effexor, and TCAs. The awareness of these
genotype deficiencies in a population will help prescribers dose antidepressants according to
clinical guidelines to prevent adverse reactions in individuals who are intermediate or poor
metabolizers or avoid drugs metabolized by those enzymes.
Participants Motivation to Adopt
Another piece of this evaluation was getting the participants (physicians, nurses,
administrators, and clinicians) to complete the Provider Motivation Adoption Scale (PMA scale)
regarding their motivation to use new technology in their work. The motivation to the adopt scale
was sent to a group of clinicians and administrators during November 2020. Of the 27 healthcare
professionals, only 12 responded to the Pre-PMA survey, with only eight surveys complete
enough to use the data.
Of the 12 that responded: 12.5% were physicians, 25% nurses, 25% administrators, and
37.5% clinical therapists. Their ages range from 55 to 64 with 62.5%, 35 to 44 with 25%, and 45
to 54 with 12.5%. Sixty-two percent (5) of the respondents were females, 25% male, and 12.5%
"other" gender. Although only one prescriber was in this group, many were nurses who could
influence care decisions. Two were administrators who could influence policy and financial
expenditures in the organization. Despite having a small number of respondents, some interesting
data emerged as presented in Table 7.
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Table 7
Providers Pre-Motivation Adoption Scale
Strongly
Strongly
Items
Disagree (1)
Agree (5)
Functional
F1
Reliability
0.0%
12.5%Saving
F2
Time
0.0%
12.5%
F3
Practical
0.0%
12.5%
F4
Facilitation
0.0%
0.0%
Conformity
Con1 Expectations
12.5%
37.5%
Con2 Advice
12.5%
37.5%
Con3 Utilization
0.0%
37.5%
Con4 Competition
25.0%
37.5%
Con5 Majority opinion
12.5%
Power 25.0%
P1
Recognition
12.5%
50.0%
P2
Career advance
25.0%
25.0% leader
P3
Opinion
12.5%
37.5%
P4
Decision makers
12.5%
0.0%
P5
Future earnings
12.5%
37.5%
P6
Pioneer
0.0%
Hedonic0.0%
H1
Passion
0.0%
25.0%
H2
Satisfaction
0.0%
0.0%
H3
Excitement
0.0%
0.0%
H4
Joy
0.0%
0.0%
H5
Enthusiasm/personal
reward 0%
0.0%
Patient Benefit
PB1 Despite High Cost
0.0%
0.0%
PB2 Increased effort
0.0%
0.0%
PB3 Patient well-being
0.0%
25.0%
PB4 Negative recommendation 0.0%
12.5%
Cognitive
Cog1 Analytical mind
0.0%
0.0%
Cog2 Intellectual
challenge
0.0%
0.0%
Cog3 Improve skills
0.0%
0.0%
Cog4 Logical thinking
0.0%
0.0%

Disagree
(2)

Neutral

Agree

(3)

(4)

12.5%
0.0%
12.5%
37.5%
50.0%
50.0%
50.0%
25.0%
12.5%

50.0%
62.5%
62.5%
62.5%

25.0%
25.0%
12.0%
0.0%

0.0%
0.0%
12.5%
12.5%
50.0%

0.0%
0.0%
0.0%
0.0%
0.0%

25.0%
50.0%
37.5%
50.0%
50.0%
37.5%

12.5%
0.0%
12.5%
25.0%
0.0%
50.0%

0.0%
0.0%
0.0%
12.5%
0.0%
12.5%

50.0%
25.0%
0.0%
12.5%
50.0%

25.0%
75.0%
75.0%
87.5%
50.0%

0.0%
0.0%
25.0%
0.0%
0.0%

25.0%
0.0%
25.0%
75.0%

37.5%
37.5%
50.0%
12.5%

37.5%
62.5%
0.0%
0.0%

12.5%
12.5%
25.0%
12.5%

87.5%
87.5%
75.0%
87.5%

0.0%
0.0%
0.0%
0.0%
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The providers' pre-motivation scale (Table 7) revealed a 62.5 to 50% agreement to
support pharmacogenomics' adoption concerning practicality, time-saving and technological
reliability. The group was 50% neutral to conform expectations and utilization of PGx; at the
same time, there were 37.5 to 25% in disagreement to attune to expectations and been pressured
by the majority to use the technology. Similarly, they disagreed a 50 to 37.5% about the power to
achieve recognition, become a key leader, and increase their earnings with pharmacogenomics'
adoption. The participants were 50.0% neutral in advancing careers, impacting decision-making,
and the benefit of being a pioneer in PGx.
The area of hedonics or to enjoy the adoption of pharmacogenomics technology had
excellent scores with 87.5% in agreement. Seventy-five percent of the group agreed with the
satisfaction and excitement of acquiring medical innovations, and 50.0% were enthusiastic about
testing a medical innovation.
About patient benefits from pharmacogenomics, 62.5% strongly agreed to adopt the
technology if it increases the patients' comfort. However, 75.0% were neutral about adopting the
technology if there were harmful recommendations. The cognitive construct or understanding
and knowledge to adopt pharmacogenomics had the highest scores with 87.5% in analysis,
intellectual challenge, and logical thinking; they scored a 75.0% in the combined medical and
intellectual skills. The responses in this area support the fact that clinical providers are highly
motivated to pursue knowledge to improve patient care. A higher group response will be more
significant to identify their preferences better.
Participants Comments
Comments received in the open text space included:
“Cost is always a concern in medical innovation.”
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“The interpretation of the testing is often cursory and confusing. Physicians have been trained to
read diagnostic testing not as interpreters but as utilizers of bottom line data. Many insurances
will not cover genomics unless failed STAR D trials from multiple categories is demonstrated.”
“The conformity and power questions seem applicable for prescribers not for clinicians. A more
broad and direct question like, “I support genetic testing for the best client care” would be
better, in my opinion.” – a clinician
Post-Participants Motivation to Adopt
Video education in pharmacogenomics was provided via email to the 27 healthcare
participants. Of this group, only three people responded to the Post-PMA scale after multiple
reminders. The DNP student received verbal feedback that the presentation was good but too
complex, so perhaps that is why not many surveys were returned. The video education was
technical in terms of the clinical use of pharmacogenomics and understanding the reports.
Perhaps a series of in-person sessions after the project is complete can be developed for an
extended discussion of the technology and case by case application.

Discussion
This quality improvement project's main goal was to identify the value of
pharmacogenomic testing (PGx) in adult patients diagnosed with major depression (MDD) who
have failed two or more antidepressants and had PGx for treatment guidance. Records review of
pre-post PHQ-9 depression scale scores in 73 subjects demonstrated response to treatment with a
decrease of 10 points in the scores mean. The secondary goal assessing providers' motivation to
adopt pharmacogenomic testing before and after an educational intervention in the topic revealed
their interest in knowledge acquisition but not motivation to adopt the technology.
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The results from a convenience sample of 73 records of patients showed a predominant
group of 72.6% females vs. 27.4% males, White European-American (86.3%) with an average
age of 44.85 years old. There was a small representation of Hispanics (8.2%) and AfricanAmerican (5.5%) subjects. These groups are a segment of the Hampshire, MA area where the
U.S. census identified an 84% White (European-American), 4.01% White Hispanic, and 2.69%
Black or African American (DATA USA, 2018). Brody et al. (2018) found in the U.S. National
Health and Nutrition Examination Survey twice the rate of depression in women 10.4% than
males with a 5.5%. The previous data and the number of females in the sample reflect that more
females are diagnosed with major depression and seek treatment.

The STAR-D study data (NIMH, 2006) demonstrated that 45.2% of the subjects failed an
average of four or more medications before treatment response. In synchrony with the STAR-D
study, this record review found a 23% of subjects failed four medications, 21.9% failed eight to
eleven and, 20.5% failed five to seven medications before pharmacogenomic testing (PGx). We
can estimate that the total sum of these subgroups, 65.4% of the subjects, failed an average of six
antidepressants before PGx. After the guided pharmacogenomic intervention, 44 (60.3%) of the
subjects responded to an average of 1.36 medications. It is worth mentioning a subgroup of 18
(24.7%) subjects had two to four medication trials post PGx.

There was a difference of 10 points from the PHQ-9 scales pre-post mean values (Table 2
& 3) with p = .000 < .001 indicating subjects had a positive and significant response to
pharmacogenomic guided medication. Twenty-two 22 (33%) subjects had scores within
remission “0 – 4 none to minimal depression”, and 35 (53%) had “5 – 9 mild depression”. These
findings are consistent with the studies from Greden et al. (2019), where 28.5% of subjects
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responded to treatment, and 21.5% had remission. Similarly, Perez et al. (2017) found a higher
response in PGx guided group than treatment as usual, 51.3% vs. 36.1%; alike, Tanner et al.
(2018) found 31% response and 15.2% remission rates in subjects with pharmacogenomic
testing.
The inclusion of the comorbid diagnoses, borderline personality disorder and history of
substance use had the additional purpose of identifying these subgroups' in the treatmentresistant depression population and exploring their response to pharmacogenomic testing.
Chapman et al. (2020) identified the epidemiology of the diagnosis of borderline personality
disorder (BPD) with a prevalence of 1.6% in the general population, a lifetime prevalence of
5.9%, and a 3:1 ratio of females vs. males in the mental health scenarios. The subjects sample
had a similar proportion of 15 females to four males diagnosed with BPD, almost 3:1 ratio.
Even though the overlap of 12 subjects in the substance use history and the BPD
subgroups, the results were significantly higher 10% > 1.5% in the history of substance use
subjects for remission "0 – 4 none to minimal depression", and 18% > 12% for response "5 – 9
mild depression" than the BPD subgroup. These findings serve to make a distinction between
genotypic and phenotypic correlates of the phenomenology of depression. Some symptoms
evolved from learned behaviors, and some symptoms stem from presumed catecholamine
neurobiology. Indeed, the results support the challenges of treating comorbid borderline
personality disorder (Chapman et al., 2020), requiring a multidisciplinary approach. It also
suggests the use of pharmacogenomic testing may improve response to psychotropic treatment in
the BPD subgroup.

The 73 subjects' phenotype findings returned a predominant White European-American
(White non-Hispanic) sample representative of the local census. Dominant percentages were in
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the intermediate metabolizer (IM) enzymes with CYP2B6 37%, CYP2C9 35.6%, CYP2C19
20.5%, UGT2B15 21.9%, and CYP2D6 19.2% (note CYP2D6 had the highest value 11% as
poor metabolizer). A worldwide meta-analysis from Zhou et al. (2017) found a 4.3% reduced
CYP2B6 in Europeans vs. 4.4% admixed Americans, reduced CYP2C9 18% European vs.
10.8% admixed Americans, reduced CYP2C19 18.5% Europeans vs. 10.7% admixed Americans,
and reduced CYP2D6 29.5% European vs. 25.3% admixed Americans.
The revision results correlate with the literature review that those individuals in the poor
metabolizers, intermediate or ultra-rapid groups, who already failed two antidepressants, will
require medication dose adjustment or an alternative antidepressant due to their metabolic
deficits (Bank et al., 2018; Dunlop et al., 2019; Greden et al., 2019; Hicks et al., 2015; Pérez et
al., 2017). Furthermore, the treatment implications for the identified genotypes based on Fabbri
and Serretti (2019) and their summary of the Clinical Pharmacogenetics Implementation
Consortium (CPIC) and the Dutch Pharmacogenetics Working Group in the Netherlands for the
dosing of antidepressants recommend a dose decrease of 25% to 50% in individuals who are
intermediate or poor metabolizers or avoid drugs processed by those enzymes.

Despite the participants' limited responses, their main areas of agreement with 87.5% to
75% were the joy to learn and test new technology and the intellectual gain and medical
knowledge derived from the new information. The second most substantial areas with a 62.5% to
50% agreement were the practical time saving and reliability of pharmacogenomics and patient
comfort. The group's most significant disagreement scores were 50% to 37.5% in conformity to
expectations to use pharmacogenomics based on peer or social pressure, the power of receiving
recognition to influence decisions, become leaders, and increase earnings from the use of the
PGx.
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Facilitators and Barriers

The agency administrative director and medical director were the main facilitators to
support this project with the records review and staff surveys. A limitation for the record review
was excluding other patients' diagnoses (e.g., bipolar disorder, anxiety disorder). A systematic
review and meta-analysis from Milosavljević et al. (2021) supported genotyping for CYP2D6
and CYP2C19 for dose recommendations after associating elevated drug levels in several
antipsychotics and antidepressants to individuals genotype deficits. The treatment of depression
and other mood disorders often requires the concomitant use of antidepressants, antipsychotics,
and other adjunct psychotropics; therefore, PGx will identify genotype deficits in the CYP 450
enzymes and other relevant genes to prevent adverse events or lack of treatment response.

There were 30 missing values from the pre-post PHQ-9 scales, a barrier to complete the
data. This required contacting patients by phone to update their information and calculate their
pre PHQ-9 scores before PGx from their documented symptoms in the electronic health record
and patients' confirmation. The agency facilitated a team of nurses to assist with the calls to
complete a meaningful sample of the scales. The timing of these calls during the current COVID
quarantine and its impact on our society's social and financial changes may have contributed to
higher depression scores in the post-PHQ-9 scales.

The possibility of recent PHQ-9 scores not representing the response to treatment but to
the traumatic pandemic experience is both a barrier and an opportunity to use a measurement
instrument. The consistent use of validated clinical instruments or measurement-based care
(MBC) is believed to be less than 20% in mental health care, despite proven to substantiate
assessment, monitor treatment, improve clinical outcomes, support policy decisions and
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therapies reimbursement (Aboraya et al., 2018; Lewis et al., 2019). Incorporating efficient,
valid, and reliable instruments for MBC is an agency clinical-policy decision that will result in
the previously mentioned benefits.

There was a limitation to obtain inferential data between the subgroups of borderline
personality disorder and substance use history due to their overlap. A more significant sample
may exclude the overlap values to comply with inferential analysis's assumption of
independence.

Several barriers may contribute to the providers' surveys' low response; the current
COVID quarantine keeps most staff working from home, with increased demand for virtual
work. The new virtual work reality may be an additional task and an obstacle for providers to
respond to a survey and watch the video education. Other factors include the providers'
perception of the complexity of understanding the pharmacogenomic technology vs. its debated
reliability. Chronic time restrictions in the health system with a constraint of 15 minutes for
medication follow up visits is a significant barrier to promote the appropriate use of PGx.
Finally, since medical providers are the primary users of the technology, the non-medical
providers may feel the technology and survey were not relevant to their needs or interest.

The previously discussed barriers to the project align with the theoretical framework of the
Diffusion of Innovation Theory by Everett Rogers (2003). Individuals need time to adopt new
ideas which will be influenced by their views and knowledge of the innovation attributes. Rogers
states that the rate of adoption is not dependent on the awareness-knowledge of the innovation.
The participants' perception of its advantage, compatibility with their work, complexity, and
trialability to manage are vital factors to influence its adoption. The providers' motivation to
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adopt pre-scale evidenced the participants' motivation and joy to adopt new knowledge, agreed
with new technology's practicality, and patients' benefit. The low response to the post-PMA did
not allow the student to identify motivation adoption changes post the video education.
Pharmacogenomic testing has been available for patients in Medicare, Medicaid, and some
commercial insurances for more than ten years. Last June 2020, Medicare updated their medical
necessity "Local Coverage Determination" (LCD) of pharmacogenomics testing for medications
with known gene-drug interaction established by FDA or the CPIC guidelines (American Society
of Health-System Pharmacists [ASHP], 2020). From a participant's comment, it is a limitation to
use PGx when most insurances, particularly commercial, require the failure of more than two
medications as recommended in the STAR-D multiple categories.

Healthcare cost analysis offers a realistic view of the high cost of psychiatric care related
to psychotropic medication failures, including patients continuing to be depressed, unable to
function in society, and the additional cost of healthcare utilization due to side effects, adverse
events, or hospitalizations. The cost benefits of using pharmacogenomic testing include a
potential health care savings for one individual of over $3,000.00 dollars a year with the use of
genetically congruent medications (Sussman Et Al., 2019).

Finally, Rogers (2003) points that organizational decisions have a slower rate than an
individual's choice. The inclusion of administrative staff in this project seeks to expand the
information cascade to promote pharmacogenomic’s adoption. The final attribute of an
innovation is its observability. The patients, providers, and administrators must observe the
benefits of a health intervention, confirming the necessary evidence for its adoption. Therefore,
the positive results from this record review of subjects' PHQ-9 scales response to treatment after
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the PGx guided intervention is instrumental in demonstrating the value of pharmacogenomic
testing in patients' care.

Conclusion
This DNP project evaluated the use of pharmacogenomic testing as a treatment resource
for adult patients diagnosed with major depression that failed two or more antidepressants,
measured by changes in the PHQ-9 depression scale pre and post pharmacogenomic guided
medication. The results demonstrated a significant decrease of 10 points mean in the post PHQ9 scores with p = .000 < .001 for treatment response (5 – 9 mild depression) in 53% of the
subjects, and 33% had scores within remission (0 – 4 none to minimal depression). A 60.3% of
patients responded to an average of 1.3 medications, and 24.7% had 2 to 4 medications post
pharmacogenomic treatment. These are significant findings under the new evidence research in
pharmacogenomics. The results are from the community population, which is burdened by social
disadvantages, substance use, and chronic mental illness.
This project provides many opportunities to continue exploring the associated factors
contributing to subjects' response to PGx: their gender, age, education, comorbid diagnosis,
medications, and genotypes. Bigger sample size will provide a better representation for statistical
inferences. A post-hoc analysis of some of the above variables may uncover information that was
not part of the primary goal.
Time is a natural barrier in any innovation; the last ten years in pharmacogenomics
research offered new evidence-based data that contribute to its diffusion of information.
Providers pre-survey demonstrated their motivation and joy for new knowledge and technology
toward patients’ care. The limited response to the post-survey did not allow to measure an
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increased motivation to adopt pharmacogenomics. A continuous dialogue in pharmacogenomics
and case discussions will be more appropriate to apply the information for clinical needs, and a
more straightforward presentation for staff might be better received. The CPIC and Dutch
Consortium guidelines for antidepressants and SSRIs are an excellent guide for prescribers to
review medications metabolized by the hepatic P450 isoenzymes and their clinical practice
implications. The guidelines apply to medication management in all medical specialties.
Nurses need to participate in pharmacogenomics clinical projects, continuing education
in the technology, and assuming an active role in promoting evidence-based diagnostics and
therapies that will improve patient care and safety. The agency adopted this project to continue
using, evaluating, and documenting pharmacogenomic testing benefits in patients' care. The
student plans to continue reporting referred patients’ responses to PGx, sharing the information
within the agency clinical team and with their primary care providers, and future publication.
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Table A1
Goals, Objectives and Expected Outcomes
Goal 1: Value of pharmacogenomic testing in adults diagnosed MDD who have failed two or
more medications
Objectives

Outcomes

Evaluate response to pharmacogenomic

Patients will show decreased

guided medications in patients

symptoms, improved treatment

examined from 2018 to 2020 with the

response, and remission evidenced by

Patient Health Questionnaire - 9 scales.

the Patient Health Questionnaire - 9
scale with five or less points by
February 2021.

Goal 2: Promote pharmacogenomic testing adoption and use in medical providers
Objectives

Outcomes

Assess providers’ motivation to adopt

Establish providers’ motivation

pharmacogenomic testing with the

baseline toward the use of

administration of the provider

pharmacogenomic testing with PMA

motivation adoption scale (PMA scale)

scale by November 2020.

by October 2020.
Promote providers’ adoption of
pharmacogenomic testing with
education in the topic by November
2020; and re-evaluate motivation with
PMA scale by February 2021.

Increase providers’ motivation to
adopt and use pharmacogenomic
testing with education in the area,
measured by positive changes in scores
in the PMA scale by February 2021.
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Appendix A
Star*D Algorithm

Source: Gaynes, B. N., Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Spencer, D., & Fava, M. (2008).
The STAR*D study: Treating depression in the real world. Cleveland Clinic Journal of
Medicine, 75 (1), 57 – 66. https:// doi: 10.3949/ccjm.75.1.57
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Appendix B
Harvard South Shore Program: Unipolar Depression Algorithm

Source: Giakoumatos, C. I. & Osser, D. (2017). The psyhcopharmacology algorithm project at the
Harvard South Shore Program: An update on unipolar nonpsychotic depression. Harvard Review of
Psychiatry, 27 (1), 33 – 52. https://doi:10.1097/HRP.0000000000000197
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Appendix C
Rogers Diffusion of Innovation Conceptual Model
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Appendix D
DNP Project Timeline
Fall 2020 – Spring 2021

Task
September October November December January February March April
DNP project
submission to
X
UMASS IRB
Submission to
agency of “Waiver
of Consent &
X
HIPPA consent
Started chart
review of pts with
X
PGx
Send agency
Providers
participation
X
consent & PrePMA survey
Emailed Providers
pharmacogenomics
X
in-service
Collected data
from agency
X
providers Pre
PMA scale
Analyzed initial
patients’ data
X
Analyzed 1st data
from agency
X
providers
Send agency
providers 2nd PMA
X
scale
Collected agency
providers 2nd PMA
X
scale
Analyze ALL final
data
X
Submit All data
reports
X
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Appendix E
Provider Agency Survey Consent Form
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Appendix F
Provider Motivation Adoption Pre – Scale (PMA)
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Appendix G
Providers Pharmacogenomic Education
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Appendix H
Provider Motivation Adoption Post – Scale (PMA)
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Appendix I
Patient Health Questionnaire 9 (PHQ-9)
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Appendix J
Email Communications With PMA Scale Author
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Appendix K
Neuroscience Education Institute Authorization
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Appendix L
Excel Data Model
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